Drugs / Carboplatin Injection
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT07383116 Background | Jan 2026 → Apr 2028 expected | non-small cell lung carcinoma | Shanghai Huaota Biopharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Carboplatin Injection | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07383116 ↗ |
| Route | Intravenous | “HB0025 combined with Pemetrexed for Injection plus Carboplatin for Injection or Cisplatin for Injection, intravenous infusion, once every 3 weeks (Q3W)” NCT07383116 ↗ |